Viewing records where tag name contains "media" View All

Markets Live: Starpharma shares rise 13 per cent following Australian launch of VivaGel BV

Apr 16th, 2019

The Australian Financial Review reported Starpharma’s share price rose 13 per cent following the company’s announcement that VivaGel® BV was launched nationwide in Australia. The article noted this was the first of many launches for the breakthrough BV product.

Read the full coverage here (paywall)

Read More

Starpharma’s US license for VivaGel® BV covered by Biotech Dispatch

Dec 20th, 2018

Biotech Dispatch featured the news that Starpharma had signed a sales and marketing license agreement for VivaGel® BV for the US market with ITF Pharma. The piece highlighted that upon launch, VivalGel® BV will be ITF Pharma’s top priority women’s health product. 

To read the article, click here.

Read More

Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors

Dec 20th, 2018

Online investor portal Proactive Investors highlighted Starpharma’s VivaGel® BV US license deal with ITF Pharma, worth $142 million plus escalating double digit royalties. The piece noted ITF Pharma’s strong pedigree in women’s health and their high-calibre team.

To read the article, click here.

Read More

Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model

Sep 5th, 2018

Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model.

Read the full article here.

Read More

Motley Fool ‘Extreme Opportunities’ Advisor Dr Anirban Mahanti covers Starpharma’s 2018 Financial Year Results

Aug 22nd, 2018

Dr Anirban Mahanti, Advisor at Motley Fool writes that FY18 was a “hugely transformative year for Starpharma”, noting the Company’s key milestones including its “smart licensing agreements” and “potentially game-changing pipeline of drugs”. Originally published on Motley Fool and republished with permission. Read the full article here

Read More

Starpharma: To win big in science, industry needs business-friendly scientists

Jul 31st, 2018

The Australian Financial Review covered Starpharma CEO Dr Jackie Fairley’s appearance at the AFR Innovation Summit, noting she highlighted that the biotech sector needs more business-friendly scientists to help hit more ‘home runs’ in medical science.

Read the full article here (paywall).

Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler for The Constant Investor

Jul 16th, 2018

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler on online investor publication The Constant Investor, where she discussed the company’s dendrimer platform technology. To listen to fully interview, click here. (Note: paywall) Read More

Starpharma CEO Dr Jackie Fairley interviewed by Alan Kohler on Talking Business

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler about how the company has taken VivaGel® BV from discovery to market and developed commercial products with its proprietary dendrimer technology platform.

To listen to the podcast, click here.

Read More

Starpharma CEO Jackie Fairley featured on Qantas’ inflight magazine Travel Insider

Jul 1st, 2018

Starpharma CEO Dr Jackie Fairley was featured in Qantas’ inflight magazine. To read the article, click here.

Read More

Starpharma on CommSec’s The Executive Series

Mar 14th, 2018

Starpharma CEO Dr Jackie Fairley speaks with CommSec’s Tom Piotrowski about the Company’s performance since March 2017, its partnership with AstraZeneca and upcoming milestones.

To view the video, click here

Read More

Starpharma CEO Dr Jackie Fairley on Channel 9’s The Today Show for International Women’s Day

Mar 8th, 2018

As part of International Women’s Day, Starpharma CEO Dr Jackie Fairley appeared with the Federal Minister for Women Kelly O’Dwyer and Today Show presenter Georgie Gardiner to discuss women in the workforce and gender equality.

To view the video, click here.

Read More

Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Jan 31st, 2018

Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals. 

Go to article (external link)

Read More

AstraZeneca plans to make better use of Australia’s innovation

Jan 23rd, 2018

The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic.
Go to the article (external link)

Read More

NDA submission for Starpharma’s VivaGel® BV

Nov 21st, 2017

BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage.

Go to article

Read More

Starpharma receives TGA marketing approval for VivaGel® BV

Oct 25th, 2017

Online financial news portal Finance News Network reported Starpharma received TGA marketing approval for VivaGel® BV, which is expected to be available in pharmacies in the new year under the Fleurstat™ brand.

Go to article

Read More

Morgans Under the Microscope Interview featuring Dr Jackie Fairley

Oct 23rd, 2017

Morgans Under the Microscope series featured Starpharma's CEO, Dr Jackie Fairley, discussing a number of key milestones that are approaching and the licensing arrangements entered into with AstraZeneca. 

Listen to the podcast (external link). 

Read More

Starpharma rockets on cancer drug hope

Sep 23rd, 2017

The Herald Sun noted strong investor interest and support for Starpharma regarding its positive phase 1 DEP® docetaxel trial and that no neutropenia was reported in any patients.

Go to article

Read More

Starpharma featured on Sky Business News

Aug 28th, 2017

Starpharma CEO Dr Jackie Fairly was interviewed on Sky Business News’ Ticky following the company’s successful Phase 3 trial results for VivaGel® BV for the treatment of recurrent bacterial vaginosis. Dr Fairley discussed the commercial significance of the announcement and liaising with the US FDA to bring the product to market.

To watch the interview, click here

Read More

Starpharma CEO on Finance News Network

Aug 24th, 2017

Finance News Network featured Dr Jackie Fairley as she discussed the company’s VivaGel® BV Phase 3 results for recurrent bacterial vaginosis, the company's sale of its agrochemical business for $35M, and progress with its DEP® drug delivery programs (both internal and external).

To watch the interview, click here

Read More

Seeking Alpha covers Starpharma

Aug 11th, 2017

Online stock market insights and research publication Seeking Alpha covered Starpharma’s Phase 3 results for VivaGel® BV for the treatment of recurrent bacterial vaginosis and noted the “substantial upside” of the announcement.

To view the article, click here.

Read More

Starpharma and Monash awarded STEM+ Business fellowships

Aug 10th, 2017

Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform.

To view the article, click here.

Read More

Hope is on the way for one of the world’s most common sexual problems

Aug 9th, 2017

Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age. 

Go to article (external link)

Read More

Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis

Aug 9th, 2017

Biotech trade publication noted Starpharma expects to file an NDA for VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) with the US FDA following the positive results of the Phase 3 trials.

Go to article

Read More

Biotech clinical trials a star performer

Aug 6th, 2017

Herald Sun covered the investor interest in Starpharma following the positive results of the company’s VivaGel® BV Phase 3 clinical trials for the prevention of recurrent bacterial vaginosis (rBV). Starpharma CEO Dr Jackie Fairley noted VivaGel® BV demonstrated sustained benefits for patients three months after their initial treatment, positioning the company to unlock a multi-million dollar global market.

Go to article (external link)

Read More

Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base

Jun 23rd, 2017

The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.

Go to article (external link)

Read More

Starpharma featured on Business IQ, Sky Business News

Jun 20th, 2017

Starpharma CEO Dr Jackie Fairley was interviewed on Sky Business News where she spoke to Business IQ host James Daggar-Nickson about dendrimer technologies and how the company develops products for a wide range of applications using the platform technology. Dr Fairley also discussed Australian innovation and the company's recent sale of its agrochemical business to global agricultural product giant Agrium.

Go to clip (external link)

Read More

Finance News Network: Starpharma sells Agrochemicals business for $35M

Jun 14th, 2017

Finance News Network noted Starpharma’s transaction to sell Starpharma Agrochemicals to Agrium Inc. for A$35M in cash consideration. The piece added that cash proceeds from the sale will allow Starpharma to focus on its core pharmaceutical development portfolio.

Go to the article (external link) 

Read More

Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land

Jun 14th, 2017

The sale of Starpharma’s agrochemical business was covered in The Land, with the article highlighting the innovation behind the Priostar® technology and how Agrium saw the acquisition as a strategic fit for their product portfolio. 

Go to article (external link)

Read More

Starpharma featured on Ticky on Sky Business News

Apr 20th, 2017

Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.

 Go to the article (external link)

Read More

Melbourne-based company develops world's first anti-viral condom

Apr 12th, 2017

 

The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.

 Go to the article (external link)

Read More

VivaGel BV phase 3 trials for prevention of BV completed

Mar 30th, 2017

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

Read More

Starpharma VivaGel® BV gets FDA fast track

Jan 13th, 2017

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

Read More

The Australian: Starpharma perks up on China condom deal

Aug 1st, 2016

The Australian’s David Rogers reports that Starpharma has signed “an exclusive license and supply agreement with Shenyang SKY and Land Latex Co for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market”.

Go to the article (external link)

Read More

The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how

May 17th, 2016

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

Read More

AAP: Starpharma licenses VivaGel BV in Aust, NZ

Mar 9th, 2016

"Starpharma is letting Aspen Pharmacare Australia market and distribute its Vivagel BV treatment in Australia and New Zealand for an undisclosed sum. Aspen will market and distribute the treatment for bacterial vaginosis, that's due to be launched in 2016, to clinicians and pharmacies. In return, Starpharma will receive royalties on net sales.

Starpharma still holds the commercialisation rights in the rest of the world."

Go to the article (external link)

Read More

The Age: Starpharma set for condom sales in China

Dec 17th, 2015

"Starpharma has signed a memorandum of understanding with a Chinese company to make and sell its VivaGel-coated condom in China...The Chinese company is a major supplier of condoms to the Chinese government's Birth Control Department and Disease Prevention Department. The so-called government market in China requires about three billion condoms each year for birth control and disease prevention."

Go to the article (external link)

Read More

The Australian: Cancer trial results prove good medicine for biotech's stocks

Nov 17th, 2015

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

Read More

The Australian: Starpharma wins EU approval for VivaGel

Sep 24th, 2015

The Australian reports that "Starpharma has been granted approval to market its VivaGel BV in the European Union's 28 member countries, where more than 260 million women live. The lubricant treats bacterial vaginosis (BV), the most common vaginal infection experienced by women around the world".

Go to the article (external link)

Read More